What is VitriVax?
VitriVax is a pioneering biotech firm dedicated to enhancing global vaccine accessibility and efficacy. The company leverages its proprietary ALTA® technology to create thermostable, single-dose vaccines. This innovation is poised to address critical logistical challenges in vaccine distribution, particularly in regions with limited cold-chain infrastructure, thereby improving health outcomes worldwide.
How much funding has VitriVax raised?
VitriVax has raised a total of $22.3M across 2 funding rounds:
Grant
$5M
Series B
$17.3M
Grant (2023): $5M with participation from Bill & Melinda Gates Foundation
Series B (2025): $17.3M led by Adjuvant Capital and RA Capital Management
Key Investors in VitriVax
Adjuvant Capital
Adjuvant Capital is a venture capital firm focused on financing innovative life science technologies that address high-burden public health challenges, investing in areas such as infectious diseases and maternal health to make impactful medical innovations accessible to underserved populations.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs and medical devices, aiming to partner with innovators to bring ideas from the lab to the clinic.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives, with a significant emphasis on global health initiatives and the accessibility of medical innovations.
What's next for VitriVax?
The substantial enterprise-level funding, including the recent strategic investment, positions VitriVax for significant scaling and further technological advancement. This capital infusion is expected to accelerate the development and deployment of their thermostable vaccines, potentially revolutionizing vaccine delivery and public health initiatives globally. The company's focus on accessibility and efficacy suggests a trajectory aimed at addressing unmet needs in infectious disease prevention.
See full VitriVax company page
